Literature DB >> 30250622

Overexpression of MARCKS indicates a poor prognosis of oral squamous cell carcinoma.

Chengjing Li1, Rong Xia1, Haowei Xue2, Yukun Hu2, Ming Sun2, Dongdong Fang1, Wenyu Yang1, Feng Xiao1, Jun Hou1,2.   

Abstract

Myristoylated alanine-rich C kinase substrate (MARCKS) is a protein kinase C substrate functioning in different physiological and pathological mechanisms. Previous studies have suggested that MARCKS is capable of influencing tumorigenesis and progression. However, a limited number of studies are available regarding the role of MARCKS in oral squamous cell carcinoma (OSCC). The present study primarily examined MARCKS expression in the OSCC tissues. Furthermore, increased expression of MARCKS was confirmed in the majority of OSCC tissues. Increased MARCKS expression was correlated with more advanced tumor stages, lymphatic metastasis and a poorer overall patient survival. Further molecular mechanistic examinations revealed that downregulated MARCKS expression inhibited the proliferation and migration of OSCC cells in vitro through interruption of MARCKS expression. In addition, the present study demonstrated that MARCKS aggravated OSCC progression via the phosphoinositide 3-kinase/protein kinase B pathway. Accordingly, the present study considered MARCKS to be a promoter of OSCC tumorigenesis and progression, with the potential utility as a biomarker of a poor prognosis.

Entities:  

Keywords:  metastasis; myristoylated alanine-rich C kinase substrate; oral squamous cell carcinoma; prognosis; proliferation

Year:  2018        PMID: 30250622      PMCID: PMC6144126          DOI: 10.3892/ol.2018.9311

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  26 in total

1.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.

Authors:  K J Livak; T D Schmittgen
Journal:  Methods       Date:  2001-12       Impact factor: 3.608

2.  PhosphoMARCKS drives motility of mouse melanoma cells.

Authors:  Xiangyu Chen; Susan A Rotenberg
Journal:  Cell Signal       Date:  2010-03-06       Impact factor: 4.315

3.  Oral squamous cell carcinoma.

Authors:  N R Saeed; J A Gold
Journal:  BMJ       Date:  1994-05-21

Review 4.  PI3K and cancer: lessons, challenges and opportunities.

Authors:  David A Fruman; Christian Rommel
Journal:  Nat Rev Drug Discov       Date:  2014-02       Impact factor: 84.694

5.  Upregulation of MARCKS in kidney cancer and its potential as a therapeutic target.

Authors:  C-H Chen; L W R Fong; E Yu; R Wu; J F Trott; R H Weiss
Journal:  Oncogene       Date:  2017-02-06       Impact factor: 9.867

Review 6.  The PTEN/PI3K/AKT signalling pathway in cancer, therapeutic implications.

Authors:  Amancio Carnero; Carmen Blanco-Aparicio; Oliver Renner; Wolfgang Link; Juan F M Leal
Journal:  Curr Cancer Drug Targets       Date:  2008-05       Impact factor: 3.428

Review 7.  The role of 80K/MARCKS, a specific substrate of protein kinase C, in cell growth and tumour progression.

Authors:  G Brooks
Journal:  Pigment Cell Res       Date:  1994-12

Review 8.  Gene therapy for the treatment of oral squamous cell carcinoma.

Authors:  S Xi; J R Grandis
Journal:  J Dent Res       Date:  2003-01       Impact factor: 6.116

9.  Myristoylated alanine-rich C-kinase substrate as a prognostic biomarker in human primary lung squamous cell carcinoma.

Authors:  Shoji Hanada; Anna Kakehashi; Noritoshi Nishiyama; Min Wei; Shotaro Yamano; Kyukwang Chung; Hiroaki Komatsu; Hidetoshi Inoue; Shigefumi Suehiro; Hideki Wanibuchi
Journal:  Cancer Biomark       Date:  2013       Impact factor: 4.388

10.  A cell-targeted chemotherapeutic nanomedicine strategy for oral squamous cell carcinoma therapy.

Authors:  Zhi-Qi Wang; Kai Liu; Zhi-Jun Huo; Xiao-Chen Li; Min Wang; Ping Liu; Bo Pang; Shi-Jiang Wang
Journal:  J Nanobiotechnology       Date:  2015-10-01       Impact factor: 10.435

View more
  1 in total

Review 1.  The Role of MARCKS in Metastasis and Treatment Resistance of Solid Tumors.

Authors:  Chun-Lung Chiu; Hongjuan Zhao; Ching-Hsien Chen; Reen Wu; James D Brooks
Journal:  Cancers (Basel)       Date:  2022-10-08       Impact factor: 6.575

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.